Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruconest for HAE Prodrome Treatment
NCT06690047Phase 4Completed
- Sponsor
- Bernstein Allergy Group and Clinical Research Center
- Start
- Aug 2018
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of c1-esterase inhibitor in hereditary angioedema (HAE) (2 arms), sponsored by Bernstein Allergy Group and Clinical Research Center. Primary endpoint: Difference in response rates in preventing HAE attacks up to 12 months. Started Aug 2018; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06690047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690047.